Alzheimer Disease

Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development

Published in Pain and Central Nervous System Week, August 20th, 2007

Medivation, Inc. (NASDAQ:MDVN) announced that it has appointed Robert Elfont, M.D., Ph.D., as vice president of clinical development. He is responsible for directing the Company's clinical development program for Dimebon(TM), its lead product candidate, in Alzheimer's disease.

"Rob's extensive experience in the pharmaceutical industry, particularly in neurologic disorders, and his expertise in leading clinical trials will be invaluable to Medivation as we advance Dimebon through clinical development," said David Hung, M.D., president and chief executive officer of Medivation. "His addition to our senior management team comes at a pivotal time as we recently completed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2007-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry